NEW BRUNSWICK, N.J., Nov. 4 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: SNT) today announced that the Company will be presenting at the 10th Annual Rodman & Renshaw Healthcare Conference, which is being held at the New York Palace Hotel from November 10-12, 2008. Sascha P. Fedyszyn, Vice President, Corporate Development of Senesco, will deliver the Company's corporate presentation on Tuesday, November 11th, at 5:20 PM ET.
Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. The firm also provides research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the private investment in public equity (PIPE) and registered direct placements (RD) transaction markets.
The conference will feature innovative growth companies and investors interested in such companies and will focus on firms within the Life Science, Energy and Natural Resources sectors, as well as firms based in promising Emerging Markets. Last year's conference, which focused solely on Life Science firms, attracted more than 2,500 investors and industry attendees and included presentations by more than 350 companies.
About Senesco Technologies, Inc.
Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, N.J.
Certain statements included in this press release are forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Actual results could differ materially from such statements
expressed or implied herein as a result of a variety of factors, including,
but not limited to: the development of the Company's gene technology; the
approval of the Company's patent applications; the successful
implementation of the Company's research and development programs and joint
ventures; the success of the Company's license agreements; the successful
conversion of the Company's letter of intent into a license agreement; the
acceptance by the market of the Company's products; success of the
Company's preliminary studies and preclinical research; competition and the
timing of projects and trends in future operating performance, as well as
other factors expressed from time to time in the Company's periodic filings
with the Securities and Exchange Commission (the "SEC"). As a result, this
press release should be read in conjunction with the Company's periodic
filings with the SEC. The forward-looking statements contained herein are
made only as of the date of this press release, and the Company undertakes
no obligation to publicly update such forward-looking statements to reflect
subsequent events or circumstances.
Company Contact: Investor Relations Contact:
Senesco Technologies, Inc. FD
Bruce Galton Brian Ritchie
Chief Executive Officer (firstname.lastname@example.org)
(email@example.com) (212) 850-5600
|SOURCE Senesco Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved